Guggenheim Capital LLC Affimed N.V. Transaction History

Guggenheim Capital LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 10, 2023	BUY	$0.66 - $1.29 $1,329 - $2,599	2,015 Added 10.0%	22,172 $16,000
Q4 2022 Feb 14, 2023	SELL	$1.1 - $2.45 $6,363 - $14,173	-5,785 Reduced 22.3%	20,157 $24,000
Q3 2022 Nov 14, 2022	SELL	$1.96 - $3.32 $292 - $494	-149 Reduced 0.57%	25,942 $53,000
Q2 2022 Aug 15, 2022	SELL	$2.27 - $4.86 $817 - $1,749	-360 Reduced 1.36%	26,091 $73,000
Q1 2022 May 16, 2022	BUY	$3.69 - $5.65 $2,084 - $3,192	565 Added 2.18%	26,451 $116,000
Q4 2021 Feb 14, 2022	BUY	$5.37 - $7.07 $32,424 - $42,688	6,038 Added 30.42%	25,886 $143,000
Q3 2021 Nov 15, 2021	BUY	$5.54 - $7.51 $109,957 - $149,058	19,848 New	19,848 $123,000

1.09M

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $520M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

Get notified when there are updates to the investment portfolio of Guggenheim Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Guggenheim Capital LLC with notifications on news.